Aug 2021: Wuxi AppTec immune profiling in drug discovery and CLDN18.2-related tumor models.
Related Content
Leverage our extensive panel of rat xenograft and syngeneic tumor models. Advantages for using rats in preclinical efficacy studies compared...
VIEW RESOURCE